| Literature DB >> 27144224 |
Stamatoula Drakopoulou1, Elissaios Kontis1, Eirini Pantiora1, Antonios Vezakis1, Despoina Karandrea2, Eftychia Aravidou3, Agathi Konti-Paphiti2, Erifili Argyra4, Dionisios Voros1, Andreas A Polydorou1, Georgios P Fragulidis1.
Abstract
Introduction and Aim. With the implementation of multimodal analgesia regimens, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are often administered for optimal pain control and reduction of opioid use. The aim of the study was to examine the effects of lornoxicam, a NSAID, on anastomotic healing employing an animal model. Materials and Methods. A total of 28 Wistar rats were randomly assigned in two groups. All animals underwent ascending colonic transection followed by an end-to-end hand sewn anastomosis. Group 1 received intraperitoneally lornoxicam before and daily after surgery. Group 2 received intraperitoneally an equal volume of placebo. Half of the animals in each group were euthanized on the 3rd pod and the remaining on the 7th pod. Macro- and microscopic indicators of anastomotic healing were compared using a two-tailed Fisher exact test. Results. The lornoxicam group significantly decreased fibroblast in growth and reepithelization of the mucosa at the anastomotic site on the 3rd pod and significantly increased occurrence of deep reaching defects, necrosis, and microabscess on the 7th pod. Conclusion. Lornoxicam administration during the perioperative period adversely affects histologic parameters of intestinal anastomotic healing. These effects of lornoxicam administration were not found to induce significant increase of anastomotic dehiscence in the rat model.Entities:
Year: 2016 PMID: 27144224 PMCID: PMC4838794 DOI: 10.1155/2016/4328089
Source DB: PubMed Journal: Surg Res Pract ISSN: 2356-6124
Figure 1Intraoperative photo, depicting the newly constructed anastomosis (black arrow).
Grading score of depth and extent of colonic wall destruction.
| Depth of colonic wall destruction | Grade | Extent of colonic wall destruction | Grade |
|---|---|---|---|
| None | 0 | No damage | 0 |
| Mucosal erosion | 1 | Focal lesions (<20%) | 1 |
| Submucosal erosion | 2 | Localized lesions (<40%) | 2 |
| Ulceration reaching muscularis propria | 3 | Widespread lesions (>40%) | 3 |
| Ulceration reaching adventitia | 4 |
Raw data and clustered and overall comparisons of histologic variables studied between controls and lornoxicam treated subjects. Comparisons were made with Fischer exact test. Variables with statistically significant differences are presented.
| Grading score |
CG3 |
EG3 |
|
CG7 |
EG7 |
| Overall | |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| CG versus EG | ||||||||
| Depth of colon destruction | 2 | 1/6 | 0/12 | 0.270 | 0/6 | 0/6 | 0.015 | 0.009 |
| 3 | 5/6 | 5/6 | 6/6 | 1/6 | ||||
| 4 | 0/6 | 1/6 | 0/6 | 5/6 | ||||
|
| ||||||||
| Fibroblast infiltration | 1 | 0/6 | 4/6 | 0.023 | 0/6 | 2/6 | 0.540 | 0.015 |
| 2 | 5/6 | 2/6 | 4/6 | 3/6 | ||||
| 3 | 1/6 | 0/6 | 2/6 | 1/6 | ||||
|
| ||||||||
| Granulation tissue | 1 | 4/6 | 5/6 | 1 | 0/6 | 4/6 | 0.002 | 0.005 |
| 2 | 1/6 | 0/6 | 6/6 | 0/6 | ||||
| 3 | 1/6 | 1/6 | 0/6 | 2/6 | ||||
|
| ||||||||
| Macrophage density | 1 | 5/6 | 5/6 | 1 | 5/6 | 0/6 | 0.015 | 0.082 |
| 2 | 1/6 | 1/6 | 0/6 | 3/6 | ||||
| 3 | 0/6 | 0/6 | 1/6 | 3/6 | ||||
|
| ||||||||
| Reepithelization | 0 | 0/6 | 4/6 | 0.005 | 0/6 | 0/6 | 1 | 0.049 |
| 1 | 0/6 | 2/6 | 0/6 | 0/6 | ||||
| 2 | 2/6 | 0/6 | 2/6 | 3/6 | ||||
| 3 | 4/6 | 0/6 | 3/6 | 3/6 | ||||
| 4 | 0/6 | 0/6 | 1/6 | 0/6 | ||||
|
| ||||||||
| Microabscesses | Presence | 1/6 | 5/6 | 0.08 | 0/6 | 5/6 | 0.015 | 0.01 |
|
| ||||||||
| Necrosis | 0 | 2/6 | 2/6 | 0.474 | 1/6 | 0/6 | 0.015 | 0.003 |
| 1 | 4/6 | 2/6 | 5/6 | 1/6 | ||||
| 2 | 0/6 | 2/6 | 0/6 | 5/6 | ||||
CG3: control group 3rd POD, EG3: experimental (lornoxicam) group 3rd POD, CG7: control group 7th POD, EG7: experimental (lornoxicam) group 7th POD, and n: number of subjects.
Statistical significance at the level of 0.05.